 After the market close on Monday, Castle Biosciences Inc NASDAQ: CSTL reported that its second-quarter revenues rose 79 YY to 22.75 million, beating the consensus of 18.93 million. The increase was attributable to more than double the number of tests delivered during the quarter. 